RxDoctor Payments Data

Allan Nassar, MD

Internal Medicine · Madera, CANPI 1033129135

Payments from drug & device makers

$948in general payments, 2019–2025

Across 65 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$225
  • AstraZeneca$162
  • Bayer$138
  • Amarin Pharma, Inc.$130
  • Gilead$122
  • Lilly USA, LLC$38
  • plus $133 from 6 others

What the payments were for

  • Food & beverage$948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$948 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$143,487
Medicare patients
324
Services billed
1,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol96$78,198
Tresiba Flextouch U-200Insulin Degludec48$48,261
OzempicSemaglutide43$47,405
EliquisApixaban33$32,923
JardianceEmpagliflozin23$19,689
Janumet XrSitagliptin Phos/Metformin Hcl14$19,105
Tresiba Flextouch U-100Insulin Degludec29$15,880
Incruse ElliptaUmeclidinium Bromide26$15,293
JanuviaSitagliptin Phosphate12$14,714
RybelsusSemaglutide12$11,435
Arnuity ElliptaFluticasone Furoate38$8,885
SymbicortBudesonide/Formoterol Fumarate15$8,452
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$6,900
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,763
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$162$86,650111 claims
Novo NordiskOzempic, Rybelsus$225$58,84055 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Madera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →